Improved understanding of genetic and genomic influences on drug disposition and action: Implications for children

Pediatric Drugs

Volumn 10, Issue 5, 2008, Pages 275-278

  Avard, Denise ^a   Joly, Yann ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Children; Pharmacogenetics; Pharmacogenomics; Pharmacokinetics

Indexed keywords

CYTOCHROME P450;

CHILD CARE; DRUG DISPOSITION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; GENOTYPE; HEALTH CARE PERSONNEL; INFORMED CONSENT; NOTE; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; RISK ASSESSMENT;

CHILD; HUMANS; INFORMATION DISSEMINATION; INFORMED CONSENT; ORPHAN DRUG PRODUCTION; PATIENT EDUCATION AS TOPIC; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHARMACOKINETICS; RISK ASSESSMENT;

EID: 50649107503     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200810050-00001     Document Type: Note

References (24)

1. The Royal Society. Personalised medicines: hopes and realities. London, UK: The Royal Society, 2005
2. Food and Drug Administration. Guidance for industry pharmacogenomic data submission. Rockville (MD): US Department of Health and Human Services Food and Drug Administration, 2005
3. Canadian Agency for Drugs and Technologies in Health (CADTH). Pharmacogenomics and warfarin therapy. Ottawa (ON): Canadian Federal, Provincial and Territorial Governments, 2007, Report no. 104
4. Woelderink A, Ibarreta D, Hopkins MM, et al. The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies. Pharmacogenomics J 2006 Jan; 6 (1): 3-7
5. McGuire AL, Caulfield T, Cho MK. Research ethics and the challenge of whole-genome sequencing. Nat Rev Genet 2008; 9 (2): 152-6
6. Leeder JS, Kearns GL. The challenges of delivering pharmacogenomics into clinical pediatrics. Pharmacogenomics J 2002; 2 (3): 141-3
7. Chance GW, Harmsen E. Children are different: environmental contaminants and children's health. Can J Public Health 1998 May; 89 Suppl. 1: S9-13, S10-5
8. Buck ML. Therapeutic uses of codeine in pediatric patients. Pediatr Pharmacother 2004; 10 (4): 1-4
9. Ross CJ, Carleton B, Warn DG, et al. Genotypic approaches to therapy in children: a national active surveillance network (GATC) to study the pharmacogenomics of severe adverse drug reactions in children. Ann N Y Acad Sci 2007 Sep; 1110: 177-92
10. Koren G, Cairns J, Chitayat D, et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006 Aug 19; 368 (9536): 704
11. Ross CJ, Katzov H, Carleton B, et al. Pharmacogenomics and its implications for autoimmune disease. J Autoimmun 2007 Mar; 28 (2-3): 122-8
12. Joly Y, Sillon G, Silverstein T, et al. Pharmacogenomics: don't forget the children. Current Pharmacogenomics and Personalized Medicine 2008; 6 (2): 77-84
13. Beardsmore CS. Ethical aspects of respiratory research in infancy and early childhood. Pediatr Pulmonol 1998 Jul; 26 (1): 64-8
14. Ross LF. Genetic services for children: who should consent? In: McKusick VA, Mahowald MB, Scheuerle AS, et al. editors. Genetics in the clinic: clinical, ethical and social implications for primary care. St Louis (MO): Mosby, 2001: 167-79
15. Patenaude AF, Senecal K, Avard D. Whither paediatric research and predisposition genetic testing? GenEdit 2006; 4 (2): 1-9
16. Henrikson NB, Burke W, Veenstra DL. Ancillary risk information and pharmacogenetic tests: social and policy implications. Pharmacogenomics J 2008 Apr; 8 (2): 85-9
17. Roses AD. On the discovery of the genetic association of apolipoprotein E genotypes and common late-onset Alzheimer disease. J Alzheimers Dis 2006; 9 (3 Suppl.): 361-6
18. Tucker L. Pharmacogenomics: a primer for policymakers. Background paper. Washington, DC: The George Washington University, 2008 Jan 28
19. Sillon G, Joly Y, Feldman S, et al. An ethical and legal overview of pharmacogenomics: perspective and issues. Med Law. In press 2008
20. Finegold P, Mathieson K, Holmes L, et al. Is the UK public ready for genetic medecine? Personalized Med 2008; 5 (1): 65-76
21. Rose AL, Peters N, Shea JA, et al. Attitudes and misconceptions about predictive genetic testing for cancer risk. Community Genet 2005; 8 (3): 145-51
22. Borry P, Clarke A, Dierickx K. Look before you leap: carrier screening for type 1 Gaucher disease: difficult questions. Eur J Hum Genet 2008 Feb; 16 (2): 139-40
23. Freund CL, Clayton EW. Pharmacogenomics and children: meeting the ethical challenges. Am J Pharmacogenomics 2003; 3 (6): 399-404
24. Caulfield T, McGuire AL, Cho M, et al. Research ethics recommendations for whole-genome research: consensus statement. PLoS Biol 2008 Mar 25; 6 (3): 430-5